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ABSTRACT 
In this study, the prognostic determinants were investigated involving bipolar patients clas-
sified into two groups-one with favourable course and outcome, and the other with clearly unfa-
vourable prognosis, based on certain recommended criteria, with intermediate prognosis were 
excluded. As compared to the poor prognosis group, the good prognosis group had lower social 
dysfunctions, lower ratings on psychopathotogy fewer indicators of neurodysfunction in form of 
neurological soft signs (NSS) and tardive dyskinesia (TD). The poor prognosis group was charac-
terized by: (i) older age at onset; (ii) more manic than depressive episodes (5:1) and (HI) lower 
levels of serum dopamine-H-hydroxylase activity (DBH). The association between poor prognosis' 
bipolar disorder having neuroleptic intolerance (TD and NSS) with low serum DBH, suggests that 
it is genetically governed. Further research in this direction seems in order, particularly the follow 
up of first episode manic disorders. 
Key Words: Bipolar disorder, dopamine -R-hydroxylase, prognosis, neurological "soft" signs, 
tardive dyskinesia, neurodysfunction 
In his original doctrine of dichotomy 
between 'manic depressive insanity' and 'de-
mentia praecox', the father of modem psychi-
atric nosology, Kraepefin (1919) introduced 
the pivotal concept of global personality 
deterioration as an invariable outcome in the 
latter. In sharp contrast to this concept, 'manic 
depressive insanity' was conceived as an epi-
sodic, remitting & relapsing disorder with inbuilt 
favourable prognosis in that, if the patients did 
*not die of exhaustion, starvation or suicide, they 
would eventually remit spontaneously. This 
major distinction between schizophrenia and 
affective disorders continued to persist, until 
relatively recently. The group of major affec-
l tive disorders remained an essentially 'good 
prognosis condition', devoid of residual symp-
tomatic or psychosocial dysfunction during 
remission when the individual patient returns 
to the pre-morbid level of functioning. 
However, this traditional view that the 
major affective disorders were a good progno-
sis condition has been called into question 
during the last three decades with several re-
ports suggesting that a sub-population (5% -
34%) of these disorders had poor social out-
come and/or poor response to treatment 
(Winokur et al.. 1969; Carlson et al., 1974; 
Johnstone et al., 1985; Harrow et al., 1990). It 
is gradually emerging, from carefully control-
led follow-up studies that from 15% to as high 
as 53% of bipolar disorders tend to develop a 
201 UTPAL GOSWAMI et al. 
chronic course and poor outcome resulting from 
treatment resistance (Keller, 1987; Corryel & 
Winokur, 1992). 
Evidence from the family studies, twin 
studies and other studies suggest that bipolar 
affective disorders are, to a great extent, 
genetically determined (Numberger & Gershon, 
1992). A major development in the study of 
affective disorders is the identification in the 
recent years, of more objective indicators of 
abnormalities of structural and functional brain 
abnormalities (Altshuler, 1993). Until recently, 
this was restricted to the domain of research in 
schizophrenia, with a large body of evidence 
from the NIMH studies by Dr Daniel Weinberger, 
using neuroimaging technology; studies have 
however, come independently from other 
investigators, confirming the same (Johnstone 
et al., 1989). 
Similarly, at one time it was believed that 
neuroleptic drugs were responsible for 
development of tardive dyskinesia (TD) only in 
schizophrenia syndrome. However, it has now 
been well documented that the diagnosis of bi-
polar disorder carried a very high risk of devel-
opment of TD (Mukherjee et al., 1986). In this 
paper, the investigators documented 35% 
prevalence rate of persistent TD. More recently, 
Meltzer (1992) have postulated that develop-
ment of TD is due to the individual's neurolep-
tic intolerance. Furthermore, recent literature 
on bipolar disorders, including neuroimaging 
studies, have provided compelling, and irrefu-
table data in support of structural and functional 
brain abnormalities in major affective disorder 
(Dolan et al., 1985; Coffman et al., 1990; 
Altschuleretal., 1991). 
Th« data from European' centres 
specializing in treatment of therapy resistant 
affective disorder also support the fact that a 
significant minority of affectively ill patients do 
run a chronic unremitting course (Ferrier, I.N., 
personal communication). 
Dopamine-beta-hydroxylase (DBH) is a 
genetic marker which is a tetrameric 
glycoprotein that catalyses the terminal step in 
the bio-synthesis of norepinephrine from 
dopamine, and therefore it is of interest to the 
researchers in biological psychiatry, with par-
ticular reference to those neurochemical inves- A-
tigations which require assessment of the nore-
pinephrine (NE) functions in major psychiatric 
disorders. Interest in DBH in psychiatric re-
search had its roots in the classical catecho-
lamine hypothesis of affective disorder that 
postulated a decrease in the NE level in de-
pressive syndrome, and elevation of NE level 
in Mania (Schildkraut, 1965; Maas, 1975). 
In fact, serum (or C3F) DBH activity has 
been extensively studied, in isolation, in 
affective disorders (Shopsin et al., 1972; 
Meltzer et al., 1976; Matuzas et al., 1982), and 
in schizophrenia. Likewise, a number of 
investigations have explored the role of DBH 
activity in TD also, either in isolation or in 
relation to TD in schizophrenia. However, as 
evident from last 15 years published literature, 
searched with the help of Medlars database, 
there is no published study, to characterize the •] 
group of bipolar disorders with risk of develop-
ing TD, using DBH as a genetic marker. Fur-
thermore, not many studies address the issues 
pertaining to 'external validation' of the poor 
prognosis bipolar disorders combining other 
variables including inadequate treatment re-
sponse, prolonged unremitting course, evidence 
of neuroleptic intolerance (Meltzer, 1992) in 
form of complications such as TD and soft 
neurological signs, rapid cycling, absence of full 
remission, neuroimaging deficits artd instabil-
ity during the course. Serum DBH activity could 
be a useful genetic marker in such a study. 
Therefore, the present study was undertaken 
with the following aims and objectives : 
1. To study how serum DBH levels of Bipolar 
Disorders compare with age and sex matched 
normal controls. 
2. To study if it is possible to delineate sub-
syndromes of TD, in terms of a genetic ^ 
enzymological marker. 
3. To study if it is possible to delineate sub-
syndromes of bipolar disorder with regard to its 
prognosis and characterize these prognostic 
variables. 
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4. To investigate if a pattern of serum DBH 
activity differentiates a sub-syndrome of poor 
t prognosis bipolar disorder that bears positive 
association with neurological soft signs and 
tardive dyskinesia. 
MATERIAL AND METHOD 
The following exclusion criteria were 
employed prior to selection of the index cases 
as these states could interfere in serum DBH 
activity-(i) history of any psychotropic drug treat-
ment during the three weeks preceding 
cojlection of the blood sample (excluding ben-
zodiazepines); (ii) any past or current history 
indicative of endocrine, metabolic or nutritional 
disorders; (iii) any history or finding (s) sugges-
tive of Huntington's chorea, epilepsy, multiple 
sclerosis, parkinsonism or other neurological 
disorders of ineffective, degenerative or 
neoplastic etiology; (iv) history suggestive of 
drug or alcohol dependence or non-dependent 
abuse during and/or immediately preceding the 
onset of present episode & (v) mixed affective 
states, bipolar II disorders, and the patients with 
uncertain ambiguous or intermediate progno-
sis were excluded. 
Patient population included 132 bipolar 
disorder cases at the level of first screening. 
The diagnosis was made consensually by two 
qualified psychiatrist at the point of referral. 
Subsequently, it was determined whether the 
particular patients belonged to 'good', 'poor", or 
'intermediate' outcome, clinically, in terms of 
outcome measures, particularly symptomatic 
recovery, social dysfunction and time spent in 
episodes vis a vis time spent in lucid intervals 
based on the operational guidelines given by 
Frank etal. (1991). 
Out of the 132 patients, 29 cases 
belonged to the intermediate prognosis group 
r and they were not further considered for 
recruitment in the study. From the remaining 
103 patients, 11 decided not to sign the written 
informed consent form and officially withdraw 
from the study, further 16 patients dropped out 
for the fear that they would run the risk of con-
tracting AIDS, and another group of 15 patients 
were unable to bring adequate and reliable in-
formants for the required information. There-
fore, finally we were left with 62 bipolar affec-
tive disorder patients fulfilling DSM-III (APA, 
1980) criteria, equally distributed to 'good' and 
'poor* outcome groups. The Research Diagnos-
tic Criteria (RDC) (Spitzer et al., 1978) defini-
tions of major depressive disorder and manic 
disorder were then applied. Only definite cases 
were included. 
Normal control population : The control group 
consisted of 65 normal volunteers, mainly from 
the staff and students of the institute who did 
not have any past history of psychiatric 
disturbances and had no first or second-degree 
relative with current and/or past history of 
manic-depressive psychosis and other 
functional psychotic disorders. 
Tools 
1. DSM III criteria (APA, 1980) and Research 
Diagnostic Criteria (Spitzer et al., 1978) for 
diagnosis of psychiatric syndromes understudy. 
2. Depression was rated by Hamilton Rating 
Scale for depression (Hamilton, 1960). 
3. Mania was rated by Bech Rafaelsen's Mania 
Rating Scale (Bech et al., 1978). 
4. Tardive Dyskinesia was diagnosed using 
Jeste et al's criteria (Jeste et al., 1979). 
Simultaneously patients were evaluated on the 
research diagnostic criteria for Tardive 
Dyskinesia (RDC-TD) by Schooler & Kane 
(1982). 
5. Neurological soft signs were rated according 
to the guidelines given by Nasrallah et al. (1983) 
with some modification in the battery as adopted 
by Kolakowska et al. (1985); altogether there 
were 13 items and each sign was rated on a 1-
3 scale (absent, present, marked), the sign-
'adventitious movements'-was excluded from 
the analysis as this was related to parkinsonian 
tremor and TD. 
An operational definition of 'NBUFO 
dysfunction' was predetermined as a total score 
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of 15 or more. 
6. Tardive Dyskinesia was rated using Simpson 
et al's scale (Simpson et al., 1979). 
7. A semistructured proforma was prepared to 
obtain the bio-socio-demographic, as well as 
the relevant clinical details such as age, sex, 
age at onset of the disorder, total number of 
episodes (with the break-up of manic and 
depressive episodes), level of recovery in 
social functioning and the outcome of treatment 
in terms of degree of resolution of symptoms 
(for a conceptual discussion regarding episode, 
recovery, response, remission etc., please 
refer Frank et al., 1991). 
8. Serum Dopamine-beta-hydroxylase activity 
was analysed in batches employing a modified 
spectrophotometric assay by Nagatsu and 
Udenfriend (1972). 
Procedural details 
During the study period, all the subjects 
in the study were hospitalized in the.inpatient 
facility of the Department of Psychiatry, 
Jawaharalal Institute of Postgraduate Medical 
Education & Research, Pondicherry, and later, 
others were admitted to the inpatient facility of 
the G.B. Pant Hospital, New Delhi, for a period 
of at least 24 to 72 hours. During this period, 
they were allowed to adapt to the conditions of 
the inpatient facility. They did not, during this 
period of adaptation, receive any neuroleptics, 
antidepressants or ECTs. All subjects under the 
study received the standard hospital diet. 
To control the circadian influences and 
resultant variations due to exercise, blood 
samples (6ml) were collected from the subjects 
who were fasting overnight, between 8 and 9 
A.M. while lying down supine. After clotting, 
samples were transported on ice, within 20 
minutes to the laboratory of the Department of 
Pharmacology, where the serum was separated, 
frozen and stored in - 20° C, immediately. All 
the samples were labelled with random number 
codes at the time of collection and storage, 
thereby the laboratory personnel were blind to 
the subjects' clinical details. Similar procedural 
precautions were taken for control group also. 
Statistical analysis was done on data 
which was square root transformed to permit 
Gaussian statistics. 
RESULTS 
The normal population (N=65) consisted 
of 36 males and 29 females in the age range 
between 25 to 49 years. The individual serum 
DBH enzymatic activity levels ranged from 2 
to 39 international units in this normal control 
group. 
Serum DBH activity levels in the nor-
mal controls (n=65) did not differ significantly 
from the serum DBH activity of the bipolar 
disorder as^ group (good and poor prognosis 
combined, n=62). 
It is important to note (Table 1) that within 
the cohort of the bipolar patients, there is no 
difference with regard to age and sex distribu-
tion of the good and poor prognosis bipolar 
disorder group. 
This is important as all the subsequent 
extrapolations do assume that these two sub-
groups have been comparable with regard to 
these variables. 
One of the important findings of the 
present study is that Poor Prognosis Bipolar 
Disorder (PPBD) patients had lower levels of 
serum DBH activity as compared to the Good 
Prognosis Bipolar Disorder (GPBD) (Table 2). 
The "PPBD" group had significantly 
TABLE 1 
AGE AND SEX DISTRIBUTION IN GOOD AND POOR 
PROGNOSIS BIPOLAR DISORDER PATIENTS 
Good prognosis Poor prognosis 
bipolar disorder bipolar disorder 
(N=31) (N=31) 
Age (in years) 
MeantS.D. 41.38±9 3« 4158±11.17 
t=0.07,d.f.=e0, N.S. 
Sex 
Male 17 t7 
Female 14 14 
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TABLE 2 
SERUM DBH ACTIVITY IN GOOD AND POOR 
PROGNOSIS BIPOLAR DISORDER GROUPS 
Serum DBH activity 
Mean so. 
Good prognosis 14.68 7.78 
Bipolar disorder 
<N=31) 
Poor prognosis 8.77 6.46 
Bipolar disorder 
(N«31) 
t*3.25, d.f. = 60,p< 001 
TABLE 3 
TARDIVE DYSKINESIA AND NEUROLOGICAL SOFT 
SIGNS IN GOOD AND POOR PROGNOSIS 
BIPOLAR DISORDER 
Good prognosis 
bipolar disorder 
<N=31) 
Tardive dyskinesia 
Present g 
Absent 25 
Poor prognosis 
bipolar disorder 
(N=31) 
19 
12 
X
2=9.6, d.f.=1, p<01 odds ratio = 6.6, 
95% CI: 1.85-24.79 
Neurological soft signs 
Present 0 
Absent 23 
17 
14 
X
2-^, d.f.=1, jx.05,14 odds ratio 3.5, 
95% C.I. :1.1-11.8 
greater frequency of Tardive Dyskinesia (n=19/ 
31) as compared to the "GPBD" group (n=6/ 
31) (Table 3; X*= 9.6; d.f.=1; p<01). 
The PPBD patients had higher frequency 
of neurological soft signs (n=17/31) as 
compared to the GPBD group (n=8/31) which 
is statistically significant. 0^=4.3, d.f =1, p<.05) 
(Table 3). 
The 'age at onset' for the bipolar disor-
der group with poor prognosis (33.6±6.4 years) 
was statistically higher than the group having 
good prognosis (25.6±5.5 years). This means 
that, younger age of onset of bipolar disorder 
may predict a favourable outcome (Table 4). 
TABLE4 
CLINICAL CHARACTERISTICS OF GOOD AND POOR 
PROGNOSIS BIPOLAR DISORDER PATIENTS 
Manic disorder 
Depressive episodes 
Total 
Age at onset 
Good prognosis Poor prognosis 
bipolar diorder bipolar disorder 
(N=3?) (N=31) 
MeantS.D. Mean ±S 0. 
2.6±15 10.3+5.3 
t=7.79, d.f. = 60, p «=.001 
2.1*1 3 5.3±3.1 
t=5.33, d.f. =60. p<001 
4.7±2.0 15.6+.5.9 
t= 9.68, d.f. =60, p< 001 
25.6±5.5 33.6±6.4 
t=5.2,d.f. =60, p<001 
iter As expected, the number of manic 
episodes in the poor prognosis group 
(N=10.3±5.3) was significantly (5 folds) greater 
than that of the good prognosis group 
(N=2.61±1.5). Similarly, when compared sta-
tistically, the mean number of depressive epi-
sodes in the poor prognosis cohort (5.3±3.1) 
was also significantly greater than that found in 
the good prognosis group (2.1±1.3) as evident 
from table 4. 
As may be expected from the character-
istics of the PPBD and those of GPBD patient 
groups, the former had very frequent episodes 
of mania and depression totalling to a mean of 
<16, as compared to the latter, who had very 
=19/ few episodes, totalling to a mean of <5 (Table 
n-6J 4). Further, the good prognosis group had bet-
ter mean social functioning and global clinical 
sncy outcome score than the poor prognosis group 
\ as (Table 5). Also the good prognosis patients 
hich spent longer time between the first and the last 
:.05) episodes (15.8±7.2 years) as compared to the 
poor prognosis patients, who had spent 
isor- relatively shorter period between their first and 
sars) the last episodes (8.93±7.9 years), 
ving On tabulating the treatment variables (i) 
5ans mainly treated with antipsychotics as opposed 
irder to those (ii) mainly treated with prophylactic 
4). drugs i.e. lithium and/or carbamazepine as in 
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TABLES 
SOCIAL FUNCTIONING SCORES & GLOBAL 
CLINICAL OUTCOME OF POOR AND GOOD 
PROGNOSIS BIPOLAR DISORDER 
Good prognosis Poor prognosis 
bipolar disorder bipolar disorder 
(N=31) (N«=31) 
Mean ±S.D. MearaS.D. 
Social funcoonlnQ, 
score 9.42*0.81 4.78*1.98 
t-12.1,d.f.-80.p<001 
Gtobai clinical 
outcome 4.6*0 5 13*0 8 
t*9.05, d.f."60, p<001 
TABLES 
FREQUENCY OF TARDIVE DYSKINESIA 
IN BIPOLAR GROUPS 
Mainly treated with Mainly trated Total 
Groups prophylactics with neuroleptics 
or antidepressants 
Tardive dyskinesia 
present e 13 1* 
Tardive dyskinesia 
absent 30 13 43 
TW"I 38 26 S2 
X
2 6.40, d.f>1, p<0.001, Odds Ratio «5. 95% confidence 
ln*s:1.7-19.1 
table 12, the frequency of TD in these groups 
were calculated and subjected to chi-square 
analysis, which shows that TD developed with 
significantly lesser frequency in those bipolar 
cases who received predominantly prophylac-
tic medication. 
DISCUSSION 
Serum DBH activity in normal population 
in this study deserves a closer look. In this 
present study it ranged from 2-39 i.u. The moot 
point is that this range (2-39 IU) is quite 'com-
pressed' as compared to the range of values 
given by the original investigators from the USA 
(3 to 100 IU) as assayed among 54 normal hu-
man sera (Nagatsu and Udenfriend, 1972). 
Therefore, one has to account for the 
lower values found in the present study. Indeed, 
Stone et al. (1974) had reported serum DBH 
activity values quite similar to those reported 
by Nagatsu and Udenfried (1972). However, 
there are reports in the 70s which published a »t 
much higher range using the same assay. 
On the other hand, several investigations 
have reported on serum DBH activity in the 
controls which were significantly lower than the 
original range cited above (Schanberg et al., 
1974;Ogiharaetal., 1975;Meltzeretal., 1976). 
Matuzas et al., (1982) have reported a much 
more restricted range of DBH activity (0 to 31 
IU), using the same assay procedure as that of 
Nagatsu and Udenfriend (1972). The present 
study has shown a slightly higher range (2 to 
39 IU). -Likewise, the normative data on DBH 
activity in Warsaw centre compares well with 
the present data Puzynaski et at., 1983). So, it 
is unlikely that any methodological factors have 
played an important role to account for this dis-
crepancy. Rather, this wide trans-ethnic varia-
tion merits further investigations with regard to 
its implications. 
Therefore, this alternative explanation 
that trans-ethnic genetic factors are operative 
and that DBH activity is actually lower in Asians, 
who may have differentially more homozygous 
population for the allele DBH-L, appears 
intriguing. Indeed, the studies in general tend 
to report lower serum DBH activity in blacks 
than in white subjects (McGuffin et al., 1976). 
Most interesting and noteworthy is, of 
course, that the normal range of the values 
reported by the Japanese investigators, 
including Nagatsu himself (Okada et al., 1976) 
have been almost identical (4 to 53 IU) to those 
reported in the present study (2 to 39 units). 
However, one has to exercise caution while 
drawing the conclusion that the Asians are low 
DBH (or low norepinephrine) people. One needs 
to undertake population studies in order to be 
entitled to draw such conclusions. 
Out of 148 bipolar disorder patients de-
tail study has been done of 132 cases as 16 
with intermediate prognosis were not included. 
None of the intermediate group had tardive 
dyskinesia. Therefore, in a consecutive series 
of 148 bipolar disorder patients, 25 cases had 
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developed TD, thereby corresponding to a 
prevalence rate of 15.5% which is higher than 
reported by the Vellpre group (Dutta et al., 
1994). This may be accounted for, among other 
factors, by the fact that the level of sensitization 
was higher in Vellore centre, leading to 
substantial reduction of false negatives. A 
differentially higher prevalence rate of TD in 
the affective disorder population as compared 
with schizophrenia has been the conclusion 
drawn by several studies conducted in the West, 
(Sandyk, 1990). 
The 15.5% prevalence of TD in bipolar 
disorder is lower than the available western 
figures; Hunt and Silverstone (1991) in their 
catchment area study reported close to 20% 
prevalence in a consecutive series of patients 
of bipolar disorder. Likewise, Mukherjee et al. 
(1986) estimated that 35% of their bipolar 
cohort suffered from persistent tardive 
dyskinesia. This difference may have been due 
to a) varying methods of drug treatment, and 
b) trans-ethnic/cross-racia! differences, as the 
methodology of the studies are comparable. 
However, other factors may have been 
operative; the neuroleptic dose is generally 
lower in India than in the West which is now 
regarded as one of the most important 
vulnerability factors in associations with 
development of TD (Cole et al., 1992; Yassa et 
al., 1992). In addition, ECT is relatively more 
frequently used mode of treatment here, which 
is reported to decrease the risk of TD (Cole et 
al., 1992). However, reports on DBH activity in 
affective disorders have attempted to correlate 
the enzyme levels in relation to subgroups of 
the disorder, as mentioned above, with posi-
tive and rewarding findings. The most impor-
tant landmark study illustrating this point was 
by Meitzer et al. (1976), which showed during 
initial analysis, that the serum DBH activity 
levels between the normal controls and that of 
psychotic and non-psychotic depressives that 
taken together, did not differ significantly. 
However, within group analysis between 
psychotic and non-psychotic depressives 
revealed that the former had significantly lower 
serum DBH values than the latter. In fact, this 
revived the interest in the study of the enzyme 
in the years that followed. 
The results of comparison between 'good' 
and 'poor
1 prognosis bipolar disordei group very 
strongly indicates that the poor prognosis 
sub-syndrome is characterized by significantly 
lower serum DBH activity levels, Actually, lower 
CSF DBH levels had been reported to positively 
correlate with increased ventricular size in 
bipolar disorder by Meitzer et al. (1994). How-
ever, there is no study of bipolar disorder with/ 
without TD in terms of DBH activity to date, so 
it would not be possible to comparatively as-
sess our findings. 
There is a trend of findings that DBH 
activity is increased as an indicator of increased 
NE activity in TD patients with schizophrenia 
and not with bipolar disorder. For example, 
Jeste et al. (1982) found a subgroup of elderly 
female TD patients with schizophrenia who had 
'high' plasma DBH activity. Nevertheless, they 
had also another group of elderly schizophren-
ics who had TD associated with low plasma 
DBH activity. 
On the other hand, in contrast to the 
previous reports, Glazer et al. (1987) failed to 
detect any significant association between 
development of TD and serum DBH activity in 
85 schizophrenic outpatients treated with 
neuroleptics. However, Markianos et al. (1983) 
found, as observed in present work, that the 
DBH activity was significantly lower in 42 of 
their dyskinetic schizophrenic cohort, using 
'median split' statistical technique, while there 
were no differences in relation to low or high 
neuroleptic dose. 
Significantly greater frequency of mod-
erate to severe TD is found in poor prognosis 
patients, who also had very significantly higher 
frequency of neurological soft signs as 
compared to the good prognosis sub-syndrome 
of bipolar disorder. These signs of neuroleptic 
intolerance (Meitzer, 1992) could be due to 
diffuse cerebral dysfunction. Indeed, if lower 
levels of serum DBH activity is reflecting lower 
hydroxylation of dopamine to NE, this would 
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alter the homeostasis of catabolic enzymes. 
Consequently, this pooled up synaptic 
dopamine, waiting to be converted to NE, as it 
were, would be metabolized by monoamine 
oxidase (MAO); this could result in an excess 
of oxy-free radicals, eventually leading to brain 
damage (Pai et al., 1994). In fact, Cohen and 
Spina (1989) have convincingly demonstrated, 
using rate models, that catabolism of dopamine 
by MAO was accompanied by release of 
hydrogen peroxide -a cellular oxidant. 
That free radicals were important factors 
in the toxicity of 6 hydroxy dopamine and 6 
amino dopamine (Cohen & Spina, 1989) were 
also supported by observations by Graham, 
D.G. (1978) who demonstrated that cytotoxicity 
of various catecholamines was directly related 
to their rate of auto-oxidation (60H DA> DA> 
NE> Epinephrine). 
These considerations become extremely 
important in the light of the fact that, in their 
earlier study, Meltzer et al. (1976) had 
postulated that significantly lower DBH activity 
may itself serve as the rate-limiting enzyme in 
the pathway of NE formation, instead of tyrosine 
hydroxylase, which would result in pooling of 
dopamine as DBH activity is lower than the 
threshold value, and it (Dopamine) is not 
converted into NE. 
The brain damage would manifest in 
several ways, including over-representation of 
tardive dyskinesia, soft neurological signs and 
'neurodysfunction', and treatment-resistance 
with poor outcome, as evident in the data 
presented in this investigation. 
A significantly greater number of patients 
without TD had received specific antimanic/pro-
phylactic agents, such as lithium and/or 
carbamazepine, whereas the TD patients group 
had been treated significantly more frequently 
with antipsychotic drugs; very few of them had 
received lithium and or carbamazepine, and this 
was statistically highly significant. This is in good 
agreement with the observation by the Dublin 
group who found that specific antimanic drugs 
such as lithium, if not given adequately, would 
increase the risk of TD; they also found, as in 
the present study, that their bipolar patients had 
fewer depressive episodes (Waddington & 
Youssef, 1988). 
In our study also, poor prognosis group 
has more number of manic episodes as com-
pared to depressive episodes. On the other 
hand, the good prognosis bipolar patients had 
significantly lesser number of episodes in total, 
manic and depressive combined. It is interest-
ing to note that the good prognosis bipolar 
patients had almost equal number of manic and 
depressive episodes. 
These findings refute the claim by Yassa 
and Schwartz (1983) that depressive states 
could be acceptable as predictor in the 
development of TD. In fact, the available 
evidence points to a very strong possibility that 
frequent manic episodes may be regarded as a 
vulnerability marker of tardive dyskinesia. 
Repeated episodes of Bipolar disorder 
have been associated with Neuroanatomic and 
Cognitive changes (Altshuler, 1993). Whereas 
it is possible that in some bipolar patients these 
anomalies may be developmental in nature 
(Nasrallah 1991; Beckmann and Jakob 1991), 
an alternative explanation for structural and 
cognitive change is that there is something 
about the process of bipolar illness that may 
be destructive to brain tissue. The possibility of 
an ongoing destructive process that 
accompanies the occurrence of each episode 
is raised. Perhaps having episodes of manias 
and depressions causes damage to brain 
tissue. 
A functional correlate of such damage 
might be persistent cognitive deficits in the 
euthymic periods. Indeed, animal data suggest 
that hypercortisolemia-a well-known finding 
present in bipolar patients during affective 
episodes-may result in toxicity to the 
hippocampus, decreased glucocorticoid 
receptor numbers and ultimately cell death and 
tissue loss in the vulnerable regions (Sapolskly 
1985). Alternatively, each manic episode is 
probably increasing the possibility of "kinding" 
(Post et al., 1984) which explains why the anti 
convulsants have significantly lesser number 
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of TD in our population under study. 
It is worthy of note that the 'age at onset' 
for the poor prognosis bipolar disorder is higher 
than the good prognosis group. This fs a find-
ing which is in disagreement with some studies 
in the West. However, there are a number of 
clinical differences between the western and 
Indian observations. 
There are important Socio-demographic 
differences, too and the age of onset of the good 
and poor prognosis bipolar disorder is one such 
patient related variable. 
In conclusion, the present investigation, 
suggests that a subgroup of poor prognosis 
bipolar disorder with tardive dyskinesia has 
been identified with the help of the genetic 
marker, serum dopamine-B-hydroxylase 
activity, having the clinical characteristics of 
frequent manic episodes, evidence of diffuse 
brain dysfunction and not having been treated 
with the primary 'anti-manic' drugs. By 
implication, the authors wish to emphasize the 
need for adequate replication of findings, and 
further stress on trie need to treat even the first 
episode of affective disorders with prophylactic 
agents. 
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